Compare ZDGE & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | LSTA |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 45.2M |
| IPO Year | 2016 | 2000 |
| Metric | ZDGE | LSTA |
|---|---|---|
| Price | $3.01 | $3.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 65.8K | 64.3K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 73.85 | 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $29,398,000.00 | ★ $35,283,868.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.97 | $1.81 |
| 52 Week High | $4.70 | $5.07 |
| Indicator | ZDGE | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 16.40 |
| Support Level | $2.91 | $2.29 |
| Resistance Level | $3.19 | $4.84 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 56.82 | 15.75 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.